Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]
Endocrine and Metabolic ScienceChronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe +5 more
doaj +3 more sources
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Pharmaceuticals, 2021 Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore,
Nina Vodošek Hojs +5 more
doaj +8 more sources
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]
Reviews in Cardiovascular MedicineCardiovascular (CV)-kidney-metabolic (CKM) syndrome is a complex disorder characterized by the co-occurrence of CV risk factors, including chronic kidney disease (CKD), hypertension, and metabolic dysfunction, which creates a vicious cycle where one ...
Biykem Bozkurt +2 more
doaj +2 more sources
Mineralocorticoid receptor antagonists promote renal immunosenescence. [PDF]
Int Urol NephrolAbstract Chronic kidney disease (CKD) is often associated with chronic inflammation, influenced by the activation of mineralocorticoid receptors (MR). This review focuses on changes in immune cells and explores the important role that MR antagonists (MRAs), especially the new nonsteroidal MRA, finerenone, play in alleviating renal and
Wang QR, Yang Y.
europepmc +3 more sources
Mineralocorticoid receptor antagonists in cardiovascular translational biology. [PDF]
Cardiovasc Endocrinol Metab, 2023 This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes.
Chilton RJ, Silva-Cardoso J.
europepmc +3 more sources
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists. [PDF]
Diabetologia, 2023 AbstractThe overactivation of the mineralocorticoid receptor (MR) promotes pathophysiological processes related to multiple physiological systems, including the heart, vasculature, adipose tissue and kidneys. The inhibition of the MR with classical MR antagonists (MRA) has successfully improved outcomes most evidently in heart failure.
Savarese G +4 more
europepmc +6 more sources
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
Vascular Health and Risk Management, 2017 Juan Carlos Yugar-Toledo,1 Rodrigo Modolo,2 Ana Paula de Faria,2 Heitor Moreno2 1São José do Rio Preto Medicine School – FAMERP, São José do Rio Preto, 2School of Medical Sciences, University of Campinas (UNICAMP ...
Yugar-Toledo JC +3 more
doaj +4 more sources
Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease [PDF]
Frontiers in PharmacologyEvery year millions die prematurely of complications related to chronic kidney disease (CKD). Main causes of death are connected with cardiovascular (CV) complications.
Mai Rosenberg, Alexei Y. Bagrov
doaj +2 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources